Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
High Dose
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Non-Hodgkin Lymphoma
100%
Cyclophosphamide
100%
Etoposide
100%
Carmustine
100%
Chronic Graft-versus-host Disease (cGVHD)
80%
Graft-versus-host Disease (GvHD)
40%
Previous Chemotherapy
40%
Chemotherapy Regimen
40%
Total Body Irradiation
40%
Non-relapse Mortality
40%
Aggressive non-Hodgkin Lymphoma
40%
Probability of Relapse
40%
High Risk
20%
Liver Disease
20%
Overall Survival
20%
Leukoencephalopathy
20%
Hematopoietic Cell Transplantation
20%
Allogeneic
20%
Follow-up Time
20%
Cyclosporine
20%
Conditioning Regimen
20%
Autologous Transplantation
20%
Recurrent Disease
20%
Event-free Survival
20%
Venous Disease
20%
Methylprednisolone
20%
Preparative Regimen
20%
HLA-matched Donor
20%
Diffuse Alveolar Hemorrhage
20%
Event Probability
20%
95% Confidence Interval
20%
Patient Median
20%
Medicine and Dentistry
Cell Transplantation
100%
Drug Megadose
100%
Non-Hodgkin Lymphoma
100%
Cyclophosphamide
100%
Etoposide
100%
Carmustine
100%
Hematopoietic Cell
100%
Graft Versus Host Reaction
33%
Patient History of Chemotherapy
33%
Whole Body Radiation
33%
Chronic Graft Versus Host Disease
33%
Acute Graft Versus Host Disease
33%
Chemotherapy
33%
Infection
16%
Overall Survival
16%
Leukoencephalopathy
16%
Event Free Survival
16%
Recurrent Disease
16%
Cyclosporine
16%
Autotransplantation
16%
Methylprednisolone
16%
Vein Occlusion
16%
Pulmonary Hemorrhage
16%
Median Follow Up
16%
Immunology and Microbiology
Hematopoietic Cell
100%
Drug Megadose
100%
Cell Transplantation
100%
Cyclophosphamide
100%
Chronic Graft Versus Host Disease
33%
Graft-Versus-Host Disease
33%
Acute Graft Versus Host Disease
33%
Overall Survival
16%
Infectious Disease
16%
Ciclosporin
16%
Autotransplantation
16%
Methylprednisolone
16%
Event Free Survival
16%
Infection
16%